Kontratar

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

SAM
N/A
Solicitation

Posted

Mar 6, 2026

Due Date

Mar 11, 2026

Location

San Antonio, Texas

Description

https://api.sam.gov/prod/opportunities/v1/noticedesc?noticeid=bc21eb281be04db5939621849299c76a

AI Summary

The Department of Defense Defense Health Agency (DHA) is issuing RFQ HT9402‑26‑Q‑9202 to obtain price quotes for pharmaceutical agents that will be considered for inclusion on the DoW Uniform Formulary (UF). Offerors must submit separate, signed quotes for the UF Blanket Purchase Agreement (BPA) and/or the UF Additional Discount Program (ADP) using the Manufacturer Quote Submission Checklist. Quotes must reference the company’s current FSS contract number, match the company name on the VA NAC Search Tool, and be equal to or lower than the prices listed on the FSS, Big 4, and Joint National Contract (JNC) sites. All package sizes (e.g., 30, 100, 1000) must be quoted, and BPA quotes must cover every size. Offerors must also agree to work with the DoW Prime Vendor Program, open a limited distribution channel to Accredo for TRICARE mail‑order (DoW only), and provide additional discounts that are equal to or less than any existing reductions on the approved FSS or National Contract price lists. Prices must remain valid for 180 days, and any price contingencies tied to the number of agents selected for the Basic Core Formulary (BCF) or Extended Core Formulary (ECF) must be identified in the NDC price lists. Interested companies must register by emailing the RFQ point of contact, submit any advanced questions for discussion at a pre‑quotation teleconference, and may request one‑on‑one technical appointments. In lieu of a clinical presentation, offerors must answer two questions via email describing the clinical advantages of the proposed drug over competitors. All quotes submitted after the deadline may be rejected, and extensions are granted at the Contracting Officer’s discretion. The evaluation will consider both clinical effectiveness and the quoted price’s impact on relative cost‑effectiveness for UF tier classification (generic, formulary, BCF, ECF, or non‑formulary).

Details

Notice ID
bc21eb281be04db5939621849299c76a
Solicitation Number
HT9402-26-Q-9202
NAICS Code
325412
Classification Code
6505

Want to track opportunities like this?

Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.

Get Started Free

Browse all federal contract opportunities